Abstract
The genomic, transcriptomic, and epigenomic characterization of concurrent intraductal carcinoma and adenocarcinoma of the prostate deepens the biological understanding of this lethal disease and provides a genetic basis for developing targeted therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have